ALPHA COGNITION INC

Insider buying by Opaleye Management signals bullish confidence in Alpha Cognition (ACOG); steady accumulation near $6.40 hints at undervaluation and upcoming clinical upside.

Opaleye’s steady stake build in Alpha Cognition signals a bullish thesis, adding capital that could lift the stock from its 52‑week low toward a $11.54 target.

Opaleye Management’s recent Alpha Cognition buy signals a tactical rebound bet—steady gains, strong price‑to‑book value, and a focus on short‑term upside.

Opaleye’s recent incremental buy of Alpha Cognition shares signals long‑term confidence amid market volatility—watch short interest, valuation swings, and upcoming earnings for a potential upside.

Opaleye Management’s fresh buy of 2.3 M shares in Alpha Cognition signals bullish confidence, boosting R&D, reducing dilution and hinting at a rebound in the health‑tech stock.

Opaleye Management’s new 2.125‑million‑share stake in Alpha Cognition signals bullish confidence, highlighting the company’s patent‑driven upside potential for investors.

Alpha Cognition’s insider buying surge signals confidence, with executives boosting holdings amid new patent filings and potential upside for investors.

Insider buying at Alpha Cognition signals management’s confidence as they buy shares and options, hinting at a possible rebound amid valuation pressures.

Alpha Cognition insiders buy zero‑cost shares and options, showing quiet confidence amid a 12% weekly dip—watch for future growth catalysts.